Oncotarget: Hyperprogression to immune blockade followed by a response with cabozantinib

Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.